JPH0247966B2 - - Google Patents
Info
- Publication number
- JPH0247966B2 JPH0247966B2 JP59113234A JP11323484A JPH0247966B2 JP H0247966 B2 JPH0247966 B2 JP H0247966B2 JP 59113234 A JP59113234 A JP 59113234A JP 11323484 A JP11323484 A JP 11323484A JP H0247966 B2 JPH0247966 B2 JP H0247966B2
- Authority
- JP
- Japan
- Prior art keywords
- thymus
- product
- acetic acid
- polypeptide
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001541 thymus gland Anatomy 0.000 claims description 65
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 60
- 239000000047 product Substances 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 35
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 238000000605 extraction Methods 0.000 claims description 18
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 16
- 239000011592 zinc chloride Substances 0.000 claims description 12
- 235000005074 zinc chloride Nutrition 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 102000007501 Thymosin Human genes 0.000 description 12
- 108010046075 Thymosin Proteins 0.000 description 12
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000013543 active substance Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229940088623 biologically active substance Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021450 Immunodeficiency congenital Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005810 radionecrosis Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08516697A GB2177402A (en) | 1985-07-02 | 1985-07-02 | Thymus-gland preparation and method for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60258120A JPS60258120A (ja) | 1985-12-20 |
| JPH0247966B2 true JPH0247966B2 (de) | 1990-10-23 |
Family
ID=10581651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59113234A Granted JPS60258120A (ja) | 1985-07-02 | 1984-06-04 | 胸腺製品の製造方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS60258120A (de) |
| CH (1) | CH659586A5 (de) |
| DE (1) | DE3421789A1 (de) |
| FR (1) | FR2583982B1 (de) |
| GB (1) | GB2177402A (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196958B (it) * | 1986-07-10 | 1988-11-25 | Ellem Ind Farmaceutica | Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche |
| DE3633651A1 (de) * | 1986-10-03 | 1988-04-14 | Alfred Dr Dick | Verwendung von fraktionen aus thymus- und milzextrakten zur behandlung der psoriasis |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5811399A (en) * | 1988-12-14 | 1998-09-22 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants |
| JPH0365161A (ja) * | 1989-08-01 | 1991-03-20 | Marudai Shokuhin Kk | 機能性食品 |
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| US6066622A (en) * | 1991-10-28 | 2000-05-23 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| RU2107692C1 (ru) | 1995-06-07 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| RU2107691C1 (ru) | 1995-03-02 | 1998-03-27 | Дейгин Владислав Исакович | Пептид и способ его получения |
| RU2290936C1 (ru) * | 2006-01-31 | 2007-01-10 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Способ получения средства для поддерживающей терапии, обладающего тканеспецифической активностью |
| RU2648466C1 (ru) * | 2016-11-01 | 2018-03-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет инженерных технологий" (ФГБОУ ВО "ВГУИТ") | Способ получения биогенного стимулятора для лечения и профилактики заболеваний сельскохозяйственных животных |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU934589A1 (ru) * | 1980-06-16 | 1985-06-30 | Военно-Медицинская Ордена Ленина Краснознаменная Академия Им.С.М.Кирова | Способ получени полипептидов |
| FR2492663B1 (fr) * | 1980-10-24 | 1985-11-08 | Vtoroi Mo G | Produit medicamenteux regulateur du t-systeme de l'immunite et son procede de preparation |
| EP0080518B1 (de) * | 1981-11-26 | 1986-10-15 | Ollendiek, Heinrich, Dr. med. | Verfahren zur Extraktion der Thymusdrüse |
| AU2079883A (en) * | 1982-09-20 | 1984-04-04 | Endorphin Inc. | Immune stimulator |
-
1984
- 1984-05-24 CH CH2550/84A patent/CH659586A5/de not_active IP Right Cessation
- 1984-06-04 JP JP59113234A patent/JPS60258120A/ja active Granted
- 1984-06-12 DE DE19843421789 patent/DE3421789A1/de active Granted
-
1985
- 1985-07-01 FR FR858510002A patent/FR2583982B1/fr not_active Expired
- 1985-07-02 GB GB08516697A patent/GB2177402A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE3421789C2 (de) | 1988-10-06 |
| CH659586A5 (de) | 1987-02-13 |
| GB8516697D0 (en) | 1985-08-07 |
| FR2583982A1 (fr) | 1987-01-02 |
| DE3421789A1 (de) | 1985-12-12 |
| GB2177402A (en) | 1987-01-21 |
| FR2583982B1 (fr) | 1989-02-24 |
| JPS60258120A (ja) | 1985-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0247966B2 (de) | ||
| JPH02502826A (ja) | 免疫欠損状態の治療のための医薬製剤 | |
| US5070076A (en) | Thymus-gland preparation and method for producing same | |
| CN109457007A (zh) | 一种胸腺肽的制备方法 | |
| US4455302A (en) | Medical protein hydrolysate, process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas | |
| EP2828281B1 (de) | Peptide zur verwaltung einer milchproduktion | |
| JP2001039879A (ja) | 胎盤エキスの精製により成る抗アレルギー剤及びその製造方法 | |
| WO2017082441A1 (ko) | 활성화된 혈소판 풍부 혈장을 유효성분으로 포함하는 동물의 창상 치료용 수의학적 조성물 | |
| US4908206A (en) | Extracts of embryonic organs, process for their preparation and pharmaceutical preparation containing them | |
| EP0432400A2 (de) | Pharmakologisch aktive Substanz BPC, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| GB2116565A (en) | A fibrinolytically active agent and a method for the preparation thereof | |
| RU2295963C1 (ru) | Способ получения иммуностимулятора | |
| SU934589A1 (ru) | Способ получени полипептидов | |
| RU2222317C2 (ru) | Средство для стимуляции эпителизации раны | |
| JP2824254B2 (ja) | 線維芽細胞増殖物質 | |
| JP3245202B2 (ja) | 新規骨形成誘導蛋白質及びそれを有効成分とする骨形成誘導剤 | |
| US4394374A (en) | Thymus gland extracts | |
| EP0254717A1 (de) | Menschliches darmhormon und verwendung | |
| JPS60243018A (ja) | ヒト内来性癌制御因子 | |
| JPS6339574B2 (de) | ||
| JPH03504507A (ja) | 癌細胞の選択的解離および傷、ケロイド、および炎症の後処理のために用いられる活性物質として適用される植物の光合成系由来タンパク質分画と、該タンパク質分画を含む薬剤学的産物 | |
| RU2203070C2 (ru) | Способ получения иммунотропных веществ из кожи свиньи | |
| RU2144826C1 (ru) | Способ получения тканевого препарата для лечения заболеваний желудочно-кишечного тракта | |
| US3919186A (en) | Method of recovering cytobiotic globulin from skin tissue | |
| RU2320354C2 (ru) | Способ получения иммуностимулирующих тимусных полипептидов, влияющих на гемопоэз |